When administered, Abatacept limits, to a variable degree, loss of stimulated C‐peptide secretion in patients with newly‐diagnosed type 1 diabetes (T1D), while reducing both circulating memory CD4+ T‐cells and T follicular helper (Tfh) cells; however, its precise mechanism of action is not known. This evidence concerns the gene CD4 and type 1 diabetes mellitus.